Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-metal hip implants effective August 31, citing slowing sales and new FDA classification.
Johnson & Johnson (NYSE:JNJ) is pulling the plug on its troubled metal-on-metal hip implant business, effective August 31.
Biomet CEO Jeff Binder tells MassDevice.com why gain sharing is bad for the medical device business and how the best is yet to come for the orthopedics sector.
Two decades after he jumped ship from the Boston Consulting Group into the orthopedic world, the business of bones and joints still fascinates Jeff Binder, despite some of the headwinds the industry has faced over the past 5 years.
Maybe that's because the CEO of Warsaw, Ind.-based Biomet, a privately held orthopedic medical device company, is experienced enough to know the industry has been counted out before.
Indiana orthopedic medical device maker Biomet posts strong Q3 sales, driven in part by last year's trauma business acquisition, but net losses widen severely.
Orthopedic devices maker and market bellwether Biomet this week posted strong 3rd quarter revenue growth, with a boost in sales in the U.S. and abroad and a new trauma acquisition performing admirably, but losses continued to widen for the Warsaw, Ind.-based medical device company.
Biomet decides to hold onto its Biomet 3i dental business after exploring a possible sale.
Biomet said it plans to hold onto its dental business after all, having mulled divesting the unit over the past 10 months.
Last June the privately held orthopedics giant said it was testing the waters of a possible sale or spinout for Biomet 3i.
The board of the holding company that owns Biomet decided March 27 "not to proceed with a spin-off," according to a regulatory filing.
Biomet CEO Jeff Binder tells MassDevice.com about the state of the orthopedics industry on the cusp of the American Academy of Orthopaedic Surgeons' annual meeting.
Next week, the eyes of the orthopedic world turn to Chicago for the annual meeting of the American Academy of Orthopaedic Surgeons.
The FDA prepares to issue new regulatory guidelines on metal-on-metal hip implants, potentially requiring companies with devices already on the market to submit new applications with clinical evidence of safety and effectiveness.
The FDA is expected to propose a new rule that would alter the regulation of metal-on-metal hips, placing the devices firmly in a higher-risk classification that requires more stringent FDA review.
Privately held orthopedic medical device company Biomet said sales jumped 9% in Q2 but losses widen
Orthopedic medical device maker Biomet said net losses increased dramatically during the 2nd quarter, despite a 9% jump in sales.